Emgality

RSS

galcanezumab

Authorised
This medicine is authorised for use in the European Union.

Overview

Emgality is a medicine used to prevent migraine in adults who have migraines at least 4 days a month. It contains the active substance galcanezumab.

This EPAR was last updated on 01/03/2019

Authorisation details

Product details
Name
Emgality
Agency product number
EMEA/H/C/004648
Active substance
Galcanezumab
International non-proprietary name (INN) or common name
galcanezumab
Therapeutic area (MeSH)
Migraine Disorders
Anatomical therapeutic chemical (ATC) code
N02CX08
Additional monitoringAdditional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under additional monitoring.

Publication details
Marketing-authorisation holder
Eli Lilly Nederland B.V.
Revision
1
Date of issue of marketing authorisation valid throughout the European Union
14/11/2018
Contact address

Papendorpseweg 83
3528 BJ Utrecht
Netherlands

Product information

18/12/2018 Emgality - EMEA/H/C/004648 - IAIN/0001

Contents

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

ANALGESICS

Therapeutic indication

Emgality is indicated for the prophylaxis of migraine in adults who have at least 4 migraine days per month.

Assessment history

How useful was this page?

Add your rating
Average
1 rating